IPP Bureau

Parmax Pharma posts Q1 FY 23 loss at Rs. 1.31 Cr
Parmax Pharma posts Q1 FY 23 loss at Rs. 1.31 Cr

By IPP Bureau - August 14, 2022

The company has reported total income of Rs. 1.56 crores during the period ended June 30, 2022

Nectar Lifesciences posts Q1 FY23 consolidated PAT at Rs. 3.89 Cr
Nectar Lifesciences posts Q1 FY23 consolidated PAT at Rs. 3.89 Cr

By IPP Bureau - August 14, 2022

The company has reported total income of Rs. 403.38 crores during the period ended June 30, 2022.

SMS Pharmaceuticals posts Q1FY23 consolidated loss at Rs. 12.76 Cr
SMS Pharmaceuticals posts Q1FY23 consolidated loss at Rs. 12.76 Cr

By IPP Bureau - August 14, 2022

The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.

Lupin receives USFDA approval for Meclizine Hydrochloride Tablets USP
Lupin receives USFDA approval for Meclizine Hydrochloride Tablets USP

By IPP Bureau - August 13, 2022

The product will be manufactured at Lupin’s facility in Goa, India.

Vascular experts establish appropriate use of IVUS in peripheral interventions
Vascular experts establish appropriate use of IVUS in peripheral interventions

By IPP Bureau - August 13, 2022

Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions

Roche gets USFDA approval of Xofluza to treat influenza in children
Roche gets USFDA approval of Xofluza to treat influenza in children

By IPP Bureau - August 13, 2022

Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age

AstraZeneca completes acquisition of TeneoTwo
AstraZeneca completes acquisition of TeneoTwo

By IPP Bureau - August 13, 2022

AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m.

Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
Enhertu approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer

By IPP Bureau - August 13, 2022

Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease

Pfizer announces positive results from Phase 3 study of 20-valent pneumococcal conjugate vaccine
Pfizer announces positive results from Phase 3 study of 20-valent pneumococcal conjugate vaccine

By IPP Bureau - August 13, 2022

Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA

Regen BioPharma develops novel dedifferentiation approach for increasing efficacy of CAR-T Cells to treat solid tumors
Regen BioPharma develops novel dedifferentiation approach for increasing efficacy of CAR-T Cells to treat solid tumors

By IPP Bureau - August 13, 2022

Company creates Younger T Cells for fighting cancer using its NR2F6 technology

Tetra Bio-Pharma secures $6,000,000 financing from Alpha Blue Ocean
Tetra Bio-Pharma secures $6,000,000 financing from Alpha Blue Ocean

By IPP Bureau - August 13, 2022

Congenica announces partnership with Avesthagen
Congenica announces partnership with Avesthagen

By IPP Bureau - August 13, 2022

New deal strengthens Congenica’s presence in India

MoU signed between Ministry of Ayush and MeitY
MoU signed between Ministry of Ayush and MeitY

By IPP Bureau - August 13, 2022

MeitY will provide technical support for digitalisation of the Ayush Sector under the Ayush Grid project for a period of three years

We must be careful in adopting global technological practices, says Union Health Secretary
We must be careful in adopting global technological practices, says Union Health Secretary

By IPP Bureau - August 13, 2022

Urged stakeholders to come up with similar digital platforms and create homegrown best practices where Indian methods and Indian solutions dominate the digital spaces

GL Chemtech partners with Edgewater Capital to accelerate growth
GL Chemtech partners with Edgewater Capital to accelerate growth

By IPP Bureau - August 12, 2022

Investment in response to increased demand for North American-based chemistry services

Latest Stories

Interviews

Packaging